Table 7.
Pretreatment | Treatment (p.o.) | Dose (mg/kg) | Lesion area (mm2) | Inhibition (%) |
---|---|---|---|---|
0.9% NaCl (i.p.) | LC | — | 56.68 ± 2.83 | — |
Carbenoxolone | 100 | 5.40 ± 0.47∗∗∗ | 90.47% | |
SmEE | 100 | 32.80 ± 2.38∗∗∗ | 42.13% | |
L-Arginine | 200 | 320.30 ± 101.5∗∗∗ | +465.10% | |
| ||||
L-NAME (i.p.) | LC | — | 120.80 ± 3.33 | — |
Carbenoxolone | 100 | 24.22 ± 1.01∗∗∗ | 79.95% | |
SmEE | 100 | 47.00 ± 2.59∗∗∗ | 61.09% | |
L-Arginine | 200 | 74.44 ± 12.80∗∗∗ | 38.38% | |
| ||||
NEM (i.p.) | LC | — | 155.30 ± 9.8 | — |
Carbenoxolone | 100 | 44.90 ± 3.15∗∗∗ | 70.51% | |
SmEE | 100 | 70.60 ± 3.93∗∗∗ | 54.54% |
The results are expressed as the mean ± SEM (n=6-7). LC: injured control group. One-way ANOVA, followed by Dunnett's multiple comparisons test; ∗∗∗p < 0.001.